ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced a new strategic alignment between AgeX ...
BioTime Inc. picked up 400 patents and applications plus other intellectual property dealing with human embryonic stem cells from Geron Inc. BioTime Inc. picked up 400 patents and applications plus ...
<0> LifeMap Sciences, Inc.Kenneth Elsner, COO781-826-7719orBioTime, Inc.Peter GarciaChief Financial Officer510-521-3390, ext. 367orJudith Segall510-521-3390, ext. 301 ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ (http ...
On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX) has received the ...
BioTime, Inc.BTX was a big mover last session, as the company saw its shares rise almost 6%. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback